Hypothyroid ataxia complicating monoclonal antibody therapy

    loading  Checking for direct PDF access through Ovid

Abstract

We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the ‘immune checkpoint inhibitor’ class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.

Related Topics

    loading  Loading Related Articles